UK markets closed

Cosmo Pharmaceuticals N.V. (0RGI.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
47.60+0.48 (+1.01%)
At close: 05:29PM BST
Full screen
Previous close47.12
Open47.45
Bid0.00 x 0
Ask0.00 x 0
Day's range46.90 - 47.65
52-week range46.90 - 47.65
Volume132
Avg. volumeN/A
Market cap7.012M
Beta (5Y monthly)1.01
PE ratio (TTM)0.36
EPS (TTM)1.30
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Cosmo and InfectoPharm Announce Signing of License and Distribution Agreement for Winlevi® in Germany, Italy and Austria

    Cosmo Pharmaceuticals N.V. / Key word(s): Agreement04-Oct-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland & Heppenheim, Germany – 04 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and InfectoPharm today announced the signing of a License and Distribution Agreement for Winlevi® (clascoterone) cream 1% in Germany, It

  • EQS Group

    Cosmo reports strong half-year 2022 financial results delivering record revenues and reaffirms 2022 full-year guidance

    Cosmo Pharmaceuticals N.V. / Key word(s): Half Year Results28-Jul-2022 / 06:06 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced strong financial half-year 2022 results, with record revenue of €41.5 million up 46.1% (H1 2021: €28.4 million), EBITDA of €14.9 million

  • EQS Group

    Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China

    Cosmo Pharmaceuticals N.V. / Key word(s): Agreement28-Jul-2022 / 06:01 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland & Shenyang, China – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and 3SBio (1530.HK) today announced the signing of a License Agreement for Winlevi® (clascoterone) cream 1% in Mainland China, Taiwan, Hong Ko